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ABSTRACT 
There have been tremendous development in the chemotherapy of cancer and researches are still developing new and more effective drugs to 
combat this disease. Thiosemicarbazides and thiosemicarbazone possess a wide range of biological applications. This key biological role is often 
related with their capability to inhibit the enzyme ribonucleotide reductase, similar to what is observed with potent anticancer drugs such as 
triapine and methisazone. Recent studies have revealed that thiosemicarbazones can inhibit topoisomerase II enzyme. This review discusses 
current advances of an emerging ‘new wave’ of thiosemicarbazide/thiosemicarbazone and their metal complexes as potent anticancer agents, mode 
of action and toxicity caused by them. 
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INTRODUCTION 
Thiosemicarbazones and their metal complexes present a wide 
range of applications that stretch from their use in analytical 
chemistry, through pharmacology to nuclear medicine[1–4]. The 
presence of amide, imine and thione groups makes them potential 
polydentate ligands[5] and it is not surprising that numerous 
thiosemicarbazone complexes have been prepared and 
characterized [6]. In addition, in the last few years there has been a 
growing attention towardsthiosemicarbazones related to their range 
of biological properties, specifically as antifungal, antiviral, 
antibacterial and anticancer agents [7-15]. 
Cancer is an important area of interest in the life sciences as it has 
been a major killerdisease throughout human history. It is not one 
disease, but a large group of diseases characterized by uncontrolled 
growth and spread of abnormal cells. Heterocyclic molecules are 
well known to play a critical role in health care and pharmaceutical 
drug design. Currently a number of heterocyclic compounds are 
available commercially as anticancer drugs and great efforts have 
been put to the identification of novel anticancer targets for novel 
anticancer drug discovery. 
For the survival of any organism, there should be a delicate balance 
between cell growth and death. This balance can get disturbed in a 
number of ways, which may lead to abnormal growth of tissue [16] 
leading to a lethal tumor or cancer [17]. According to WHO, cancer is 
a leading cause of death worldwide and accounted for 7.6 million 
deaths in 2008 and the same are projected to continue to rise to 
over 11 million in 2030. Antineoplastic or anticancer drugs prevent 
or inhibit the maturation and proliferation of neoplasms. They travel 
the body and destroy cancer cells. Many of the side effects associated 
with antineoplastic agents occur because treatment destroys the 
body's normal cells in addition to cancerous cells [18]. 
Cancer is a multi-step disease incorporating physical, 
environmental, metabolic, chemical and genetic factors, which play a 
direct and/or indirect role in the induction and deterioration of 
cancers. Emergence of resistance to anticancer drugs poses a major 
clinical challenge in successful treatment of cancer since some tumor 
cells develop a particular phenotype, called multidrug resistance 
(MDR), which makes these cells resistant to other classes of 
anticancer agents to which the tumor cells have not been treated 
previously. MDR cell lines have been shown to display a complex 
spectrum of biochemical and cytogenetic changes such as the over-
expression of p-glycoprotein, increased levels of glutathione related 
enzymes, down regulation of mono-oxygenases, and altered 
expression of protein kinase C [19]. 
Biological properties of thiosemicarbazones have been studied since 
1956 when Brockman etaIreported the antitumour properties of 
thiosemicarbazones derived from 2-formylpyridine. The nature of 
the substituent attached at 4-N influences the biological activity, 
while the acid character of the 3NH allows the ligand to be anionic 
and conjugation to be extended to include the thiosemicarbazones 
moiety. It has been proposed that this conjugated system enhances 
the antitumor activity. 
Metal thiosemicarbazonate complexes are also potential anticancer 
and chemotherapeutic agents which exhibit inhibitory activities 
against most of the cancers through inhibition of a crucial enzyme 
obligatory for DNA biosynthesis and cell division, viz. ribonucleotide 
diphosphate reductase (RDR) [20]. Some thiosemicarbazones even 
increase their antitumour activity by their ability to form chelates 
with specific metal ions [21]. It was reported that the anticancer 
activities of thiosemicarbazones were closely related to the parent 
aldehyde or ketone group, metal chelation ability and terminal 
amino substitution. Among them, the parent aldehyde or ketone 
group was considered critical for the anticancer activity of 
thiosemicarbazones. Heterocyclic thiosemicarbazone showed higher 
activity compared with aromatic thiosemicarbazones[22]. 
All prophecies made by scientists in the last century that cancer will 
be curable in the 21stcentury turned out to be wrong. Although the 
long-term goal still remains to make this life threatening disease 
curable one day, we have to accept at present that our 
understanding to do so is yet not comprehensive enough. The short-
term goal is, thus, to turn the deadly disease into a chronic one so as 
to elongate the survival time of the cancer patients with a maximum 
of life quality. In order to reach this short-term goal, two features of 
cancer have to be taken into account. First, the growth of the tumor 
must not exceed a certain size, so that the related organ is not 
seriously affected in its function. Second, the spreading of the tumor 
and the development of (micro-) metastases must be inhibited. In 
this review, work done by various researchers in light of 
thiosemicarbazides/thisemicarbazones and their derivatives as 
potential antineoplastic agents has been summarized. Concern has 
also been given to the mode of action and side effects caused by the 
usage of anticancer drugs (generally) affecting the normal 
metabolism of the body.  
Different derivatives of thiosemicarbazide as anti-cancer agents 
Thiosemicarbazide is an important structural motif that has the 
potential to display chemical functionality in biologically active 
molecules. Optimization of this structure can result in 
groundbreaking discovery of new class of anticancer agents. 
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SAR (Structural Activity Relationship) studies showed that a large 
number of thiosemicarbazones of N-heterocyclic compounds have 
low π-electron density at the side chain part and the ring N-atom 
should be reasonably a good electron pair donor to transition metals 
to form co-ordination compounds [23]. Thiosemicarbazones in their 
neutral or deprotonated form, behave as a N,N,S-thiodentate chelate 
towards metal ions essential for life. It displays antiproliferative 
activity on different tumors cell lines and has been a common 
feature of all compounds with carcinogenic potency. A strong 
correlation was found between tumor growth rate and the enzyme 
Ribonucleoside Diphosphate Reductase (RDR) [24]. So, it has been 
suggested that an inhibitor to RDR would be a good agent for the 
treatment of cancer. 
Moore et. al found that the antitumor activity of thiosemicarbazone 
compounds is due to their ability to inhibit ribonucleotide reductase 
(RR), a necessary enzyme for DNA synthesis [25].  
Yousef et. al (2011) [26] synthesized a series of thiosemicarbazide 
derivatives by the reaction of 4-(2-pyridyl)-3-thiosemicarbazide 
with phenyl isothiocyanate, benzoyl isothiocyanate, phenyl 
isocyanate and 4-pyridyl isothiocyanate. The products were N1-
phenyl-N2-(pyridin-2-yl) hydrazine-1,2-bis (carbothioamide) 
(H2PPS), N-phenyl -2-(pyridine-2-ylcarbamothioyl) hydrazine 
carboxamide (H2PBO), 1-(amino (thioformyl)-N-phenylform)-4-
(pyridine-2-yl)thiosemicarbazide (H2APO) and 1-(aminoN-
(pyridine-3-yl)methanethio)-4-(pyridine-yl)thiosemicarbazide 
(H2PPY) respectively.  
Among these compounds, H2PPY was found to remarkably prolong 
the lifespan of Ehrlich Ascites Carcinoma (EAC) bearing rats and 
brought their altered haemoglobin and RBC values to near normal 
values. In addition to this, In vivo studies were also made inducing 
hepatocellular carcinoma (HCC) in rats. H2PPY showed a substantial 
improvement on both biochemical and histopathological 
parameters. In the EAC bearing rats, cells were present in the 
peritoneal cavity and the compounds were administered directly 
into the peritoneum. The presence of two pyridine moieties and two 
–SH equivalent groups (C=S) in H2PPY enhanced the antitumor 
activity significantly and therefore was found to contribute towards 
the activity among the tested compounds.  
Zhang et. al. in 2011 [27] synthesized a number of 
chalconethiosemicarbazide derivatives (Ia-Ix) (Table 1) having the 











Structure of chalconethiosemicarbazide derivatives (Ia-Ix)
 
Table 1: It shows various derivatives of chalconethiosemicarbazide [27] 
Compound R1 R2 R3 R4 R5 
Ia F H H H H 
Ib Cl H H H H 
Ic Br H H H H 
Id OMe H H H H 
Ie H H F H H 
If H H OMe H H 
Ig H H NO2 H H 
Ih H F H H H 
Ii H Cl H H H 
Ij H Br H H H 
Ik H Me H H H 
Il H OMe H H H 
Im H NO2 H H H 
In H Ph H H H 
Io H OCH2Ph H H H 
Ip H H H H H 
Iq H H H H Br 
Ir H H H H Me 
Is H H H H OMe 
It H H H H Cl 
Iu H H H Cl Cl 
Iv H F H H Br 












The compounds were evaluated for their biological activities as 
potent anticancer polymerization inhibitors and antiproliferative 
activity against human hepatocellular liver carcinoma (HepG2) cell. 
Most of the compounds exhibited remarkable effects on 
antiproliferative activities and also displayed potent inhibitory effect 
on the activity of EGFR kinase, but compound Irwith p-substituted 
methyl group at B ring, was found to be most potent for that.  
The results of EGFR inhibitory activity of the tested compounds 
were corresponding to the structural relationships of their 
anticancer activities.  Magdy et. al synthesized different thio 
semicarbazide derivatives of 4-(3-(Benzofuran-2-yl)-1-phenyl-1H-
pyrazol-4-yl)-2-hydrazinyl-1,6-dihydro-6-oxopyrimidine-5-
carbonitrile, among which some were found to be quite effective 
against human liver carcinoma cell line (HEPG2).  
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The studies showed that the heterocyclic rings such as hydrazinyl as 
side chain inthiosemicarbazide derivatives were essential for the 
antitumor activity [28]. 
Aysel et. al studied thiosemicarbazone derivatives of some Schiff 
bases and found their antitumor activity [29]. The derivatives were 
found to help in decreasing the level of lipid peroxidation in tissues 
which otherwise forms carcinogenic products. 
Hitesh et. al synthesized [30] a series of thiosemicarbazones of 1-(5-
chloro-1H-benzimidazol-2-yl)ethanone (IIa-e) and studied their in 
vitro antitumor activity against 60 human cell lines derived from 
nine clinically isolated cancer types (e. g. Leukemia, lung, colon, CNS, 
melanoma, ovarian, renal, prostate and breast) according to a 
standard protocol established at the National Cancer Institute, 











Where, R = H (a); R = C6H5 (b); R = CH2CH3 (c); R = C4H9 (d); R = C6H11 (e) 
They found that compound II(b), a phenyl substituted agent showed 
remarkable activity against most of all the cancer cell lines. At a 
concentration of log10(-4.3) M, cell arrest was observed for various 
cell lines. Compound II(b) showed 100% inhibition for cell line NCI-
H460 (non-small lung cancer), SW-620 (colon cancer), SK-MEL-5 
(melanoma), RXF-393 (renal cancer) and DU-145 (prostate cancer). 
In ovarian cancer, maximum 96% inhibition for OVCAR-4 cell line, in 
breast cancer 91% growth inhibition for MDA-MB-468 cell line and 
in leukemia, maximum 49% inhibition for HL-60(TB) cell line was 
noticed. 
Serda et. al designed two new anticancer agents (III and IV) by 
combining active moieties of known potency, quinoline and 
thiosemicarbazonebioeffectors [31]. The compounds were found to 




















Metal complex of thiosemicarbazide/thiosemicarbazone and 
their derivatives 
Metal thiosemicarbazides and thiosemicarbazone complexes are 
emerging as new class of experimental anticancer chemotherapeutic 
agents which show inhibitory activities against cancer. As 
thiosemicarbazones are nitrogen and sulfur atom donor ligands 
particularly for transition metal ions [32-34], remarkable biological 
activities are observed for these compounds, related to their metal 
complexing ability in enzymes. Some pharmaceutically promising 
thiosemicarbazide derivatives have additional functional groups 
which are not co-ordinated to their “primary” metal ion. Thus 
biological activity also depends on the non-coordinating groups. 
There has been a stronger focus in recent years on substituted 
ligands, serving an important purpose in complexation with metal 
ions. They have been used as drugs and are reported to possess a 
wide variety of biological activities against bacteria, fungi and 
certain type of tumors and are also a useful model for bioinorganic 
processes [35-36]. The suggestions that thiosemicarbazones act as 
iron chelators, interfers with DNA synthesis to prevent its 
production led to a lot of interest in their complexation as well as 
their pharmaceutical importance [37]. Thiosemicarbazone 
complexes possess imine group (-N=CH-) which imparts the 
biological activity and chelating properties towards the central 
metal atom. As potential antitumor agents, copper complexes of 
aromatic thiosemicarbazones affected the complicated mechanism 
of leukemic transformations by inhibiting the replication and 
triggering apoptotic processes [38].  
Some promising novel phytochemicals quercetin thio semi 
carbozone(QTSC) copper(II)metal complex, quercetin 3-O-glucoside 
thiosemicarbozone (QOTSC) Copper(II)metal complex and their 
rutin have been synthesized and characterized by Subrahmanyam 
Naiduet al.[39] as anti-oxidant, anti-tumor, anti-cancer, anti-viral, 
anti-malarial, anti-fungal, and anti-microbial agents. In vitro, 
anticancer activity was also carried out against some cancer cell 
lines. The spectral and other data indicates that all the Cu(II) metal 
complexes are tetrahedral and octahedral(rutin) structure. Theyalso 
synthesized the schiffs bases of certain of the constituents viz. 
flavanoids / phytochemicals and later synthesized their transition 
metal complexes especially with Platinum, Gold, Palladium, 
Ruthenium, Cobalt, Iron, Nickel, Zinc and Chromium. The precursors, 
the derivatives/analogues and the transition metal complexes, all 
were excellent candidates as anticancer drugs. 
Due to the anti-proliferative properties of cobalt-thiosemicarbazone 
complexes, the production of [55Co](III)-bis-(2-acetylpyridine 
thiosemicarbazone) ([55Co](III)[APTS]2) was investigated [40]. Co-
55 (T1/2=17.53 hr) was produced by 150 μA irradiation of a natural 
nickel target by 15 MeV protons. 55Co was separated from the 
irradiated target material using a two-step method with a 
radiochemical yield of >95% followed by radionuclidic and chemical 
purity control. [55Co](III)chloride was mixed with 2 acetyl 
pyridinethiosemicarbazone for 30 min at room temperature to yield 
[55Co](III)[APTS]2 (radiochemical purity> 98% shown by 
RTLC/HPLC). A specific activity of about 10–20 Ci/mmol was 
obtained. The final solution was diluted in normal saline to 5% 
ethanolic solution for biological evaluation. The stability of the final 
product was checked in the absence and presence of human serum 
at 37°C. The partition co-efficient of the final complex at pH 7 was 
1.00±0.08. A significant tumor accumulation (%ID/g; 3.5%) was 
observed in tumor tissue 21hr post injection in fibrosarcoma-
bearing mice by biodistribution studies. Co-incidence imaging also 
demonstrated tumor uptake from 21–35hr however 35 hr tumor 
uptake is more specific and significant. 
David et al. [41] discovered that the metal-chelating compound 
Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which 
displays potent and selective antitumor activity. This compound is 
receiving translational attention, but its mechanism is poorly 
understood. Studies using the lysosomotropicfluorochromeacridine 
orange established that the copper–Dp44mT complex 
(Cu[Dp44mT]) disrupted lysosomes. This was confirmed with 
pepstatin A–BODIPY FL, which showed redistribution of cathepsin D 
to the cytosol with ensuing cleavage of the proapoptotic BH3 protein 
Bid. Redox activity of Cu[Dp44mT] caused cellular depletion of 
glutathione, and lysosomal damage was prevented by co-treatment 
with the glutathione precursor N-acetylcysteine. Copper binding was 
essential for the potent antitumor activity of Dp44mT, as 
coincubation with nontoxic copper chelators markedly attenuated 
its cytotoxicity. Topoisomerase II (Topo II), an ATP-dependent 
enzyme is an important chemotherapeutic target in the treatment of 
cancer and regulates the conformational changes in DNA topology 
necessary for transcription, replication and chromosome 
condensation and segregation [42-43]. Currently, six Topo II 
inhibitors (etoposide, teniposide, doxorubicin, daunorubicin, 
idarubicin, and mitoxantrone) are prescribed as highly anti-
neoplastic drugs in clinical use. Efforts have been made by many 
research groups to find new chemicals with improved bioactivity.  
It has been reported that thiosemicarbazones (TSCs) are potent 
antitumor agents that inhibit Topo-II. The relationship between the 
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In vitro and In vivo behavior of novel 64Cu-thiosemicarbazide 
complexes and the expression of Topo-II activity has been developed 
by Wei and group [44]. They prepared four 4N-
azabicyclo[3.2.2]nonanethiosemicarbazide derivatives (V-VIII) and 
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All the four compounds were examined by PET (positron emission 
tomography), which is a noninvasive imaging technique that 
delineates physiologic processes, complementing the high-
resolution anatomic images of MRI and CT that can reveal important 
information about location of disease. Physiologic information from 
PET can significantly aid the diagnosis of disease and help direct 
treatment for individual patients. Of the 4 ligands examined in this 
study (V-VIII), VII had significantly higher growth-inhibitory 
activities when complexed with nonradioactive copper with IC50 
value of 0.004 µmol/l in HT29 cells [44]. 
Synthesis, charecterization and nuclease activity of Au(III)-
complexes of alloxanthiosemicarbazone (All. Tsc) and substituted 
thiosemicarbazones have been reported [45]. Some hitherto 
unknown complexes of alloxanthiosemicarbazone and substituted 
thiosemicarbazones with Au(III) have been synthesized and 
characterized by elemental analysis, spectral viz. FT-IR, NMR, UV-
VIS, mass, magnetic, thermal and conductance studies. All the 
complexes were crystalline powders decomposed by mineral acids 
and tetrahedral in shape. The ligand, its schiff’sbases and metal 
chelates were screened in-vitro for anticancer activity against some 
cancer cell lines. 
Zheng et al..reported the synthesis, crystal structure and antitumor 
study of an Iron(III) complex of 2-acetylpyrazine N(4)-
methylthiosemicarbazone. The title complex [Fe(C8H10N5S)2]Cl has 
been synthesized from 2-acetylpyrazine N(4)-
methylthiosemicarbazone and FeCl3.6H2O and characterized by 
elemental analysis, IR spectroscopy and single-crystal X-ray 
diffraction. The complex consists of discrete monomeric molecules 
with octahedrallyhexaco-ordinated iron(III) ions, in which two 2-
acetylpyrazine 4-methylthiosemicarbazone units act as meridional 
NNS tridentate ligands co-ordinated to the central iron atom 
viapyrazine nitrogen, azomethine nitrogen and sulfur atoms. 
Hydrogen bonds link the complex components to stabilize the 
crystal structure. The antitumor activity of the title complex was 
tested against K562 leucocythemia and BEL7402 liver cancer cell 
lines. The complex exhibits higher antitumor activity as compared to 
the free ligand[46]. 
Arsenic compounds are natural substances used in China for medical 
treatment for more than twenty-five centuries. Particularly, arsenic 
trioxide (As2O3) has been used for ten years in patients with acute 
promyelocytic leukemia (APL). It is apparent that arsenic trioxide is 
a successful treatment for APL. Furthermore, arsenic trioxide is safe 
and effective not only in patients with leukemia, but also in patients 
with many other malignancies [47]. There is promising evidence of 
the activity of arsenic trioxide plus ascorbic acid in 
refractory/relapsed myeloma. The mechanism of potentiation by 
ascorbic acid is due to intracellular glutathione depletion. This 
treatment has acceptable toxicity and ascorbic acid does not alter 
the pharmacokinetics of arsenic trioxide [48]. 
Due to the anti-proliferative properties of platinum group-
thiosemicarbazone complexes, the production of 191Os-labeled 2-
acetyl pyridine 4-N-methylthiosemicarbazone (191Os-APMTS) was 
investigated [49]. 191Osmium (T½= 15.4d) was produced via 
190Os(n,γ)191Os nuclear reaction using enriched target irradiated 
with thermal neutrons. Reaction of in-house synthesized 2-
acetylpyridine thiosemicarbazone (APMTS) with 191Os yielded 
[191Os]APMTS checked by ITLC followed by stability, partition co-
efficient and bio-distribution determination. The complex was 
prepared with a radiochemical purity of more than 95% (RTLC) and 
specific activity of 21.5 GB/mM and was stable in the formulation 
and presence of human serum at 37°C for up to 48hr. The partition 
coefficient was determined (log P. 1.23). The bio-distribution study 
up to 4 days demonstrated significant tissue uptake differences in 
the bone, blood, heart and thyroid. This is the first Os-191 labeled 
thiosemicarbazone designed as an in-vivo therapeutic radionuclide 
generator. Further investigation is ongoing on the evaluation of the 
complex in tumor bearing animals. 
Pt(II), Pt(IV), Pd(II) and Pd(IV) complexes with 3-amino-α-
tetralonespiro-5’-hydantoin as carrier ligand were synthesized [50] 
and characterized by elemental analysis, IR and 1H NMR spectra. A 
cis-square planar structure of all the complexes (cis-[ML2Cln], 
where M is Pt(II), Pt(IV), Pd(II), Pd(IV), n = 2 or 4)was demonstrated 
with ligands coordinated via-NH2 group. Cytotoxic activity of the 
complexes were determined In vitro by MTT method against SKW-3 
human tumor cell line. All studied complexes evoked concentration-
dependent cytotoxic effects, which were much more manifested at 
micromolar concentrations. The IC50 values of the tested metal 
complexes showed that Pt(II) complex with 3-amino-α-
tetralonespiro-5’-hydantoin has higher cytotoxic activity than the 
palladium complexes with the same ligand, which confirmed the 
higher activity of platinum complexes than corresponding palladium 
complexes. 
The preparation of palladium(II)complexes of 3,5-diacyl-1,2,4-
triazole bis(thiosemicarbazone) (H2L2) [PdCl2(H2L2)], 2,6-
diacylpyridine bis(thiosemicarbazone) (H2L3) [PdCl2(H2L3)]and 
benzyl bis(thiosemicarbazone)(H2L4) [PdCl2(H2L4)]was described. 
The crystal and molecular structure of PdL4-DMF (Lsbideprotonated 
form of benzyl bis(thiosemicarbazone))was determined by single-
crystal X-ray diffraction: green triclinic crystal, as 10.258(5), 
bs10.595(5), cs11.189(5)A°, as 97.820(5), bs108.140(5), 
gs105.283(5)8, space group P1, Zs1. The palladium atom is tetra co-
ordinated by four donor atoms (SNNS) from L4 to form a planar 
tricyclic ligating system. Cytotoxic activity of compound against 
several human, monkey and murine cell lines sensitive (HeLa, Vero 
and Pam 212)and resistant to cis-DDP (Pam-ras) suggests that 
compoundsmight be endowed with important antitumor properties 
since it shows IC50 values in a mM range similar to those of cis-DDP 
[cis-diamminedichloroplatinum(II)]. Moreover, compoundsdisplay 
notable cytotoxic activity in Pam-rascells resistant to cis-DDP (IC50 
values of 78 mMvs 156 mM, respectively). On the other hand, the 
analysis of the interaction of this novel Pd-thiosemicarbazone 
compound with DNA secondary structure by means of circular 
dichroism spectroscopy indicates that it induces the double helix 
conformational changes different from those induced by cis-
DDP[51]. 
Synthesis, characterization and nuclease activity of Ru(III)-
complexes of isatinthiosemicarbazone (Is. Tsc) and substituted 
thiosemicarbazoneswas investigated by Kalyaniet al. [52]. Some 
extremely novel and hitherto unknown complexes of 
isatinthiosemicarbazone and substituted thiosemicarbazones with 
Au(III) have beensynthesized and characterized by elemental 
analysis by spectral (FT-IR, NMR,UV-Vis, mass), magnetic, thermal 
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and conductance studies. All complexes arecrystalline powders 
decomposed by mineral acids. The spectral and other dataindicate 
that all the Ru(III) complexes are tetrahedral. The ligand, its 
Schiff’sbases and metal chelates would be screened in-vitro for 
anticancer activityagainst some cancer cell lines. 
Gangadharanet al. [53] investigated the synthesis, thermal and 
antitumour studies of Th(IV) complexes with furan-2-
carboxaldehyde4-phenyl-3-thiosemicarbazone. The composition 
and structure of the metal complexes were proposed based on 
elemental analysis, molar conductivity measurements, FTIR and 1H-
NMRspectroscopy. The Schiff base behaves as a neutral bidentate 
ligandcoordinating through the azomethine N and the thio keto S 
atoms. From variousstudies, complexes were ascertained the 
general formula [ThL2X4] and[ThL2Y2], where X represents NO3–, 
NCS–, CH3COO–, CH3CHOHCOO–,ClO4– and Y represents SO42–and 
C2O42–. The thermal behavior of nitrato andoxalato complexes was 
studied and kinetic and thermodynamic parameters were calculated 
using the Coats-Redfern Equation. The ligand and a 
representativecomplex [ThL2(NO3)4] were screened In vitrofor their 
antitumouractivity against human cervical cancer cell line (HeLa). 
Inorganic complexes of uranyl with N-donor ligands were 
synthesized and characterized by FTIR and UV, ¹HNMR, ¹³CNMR 
spectra, TG/DTG measurements and some physical properties [54]. 
The results of simultaneous TG-DTG-DTA analyses of the complexes 
show that the final degradation product for these complexes is UO3. 
The antitumor activity of used ligands and their complexes against a 
panel of human tumor cell lines (HT29:Hauman colon 
adenocarcinoma cell line T47D: human breast adenocarcinoma cell 
line) were studied and determined by MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide) assay. These data suggest 
that some of these compounds provide good models for further 
design of potent antitumor materials. Also the results show that 
chelation causes drastic change in the biological properties of the 
ligands and also the metal moiety. So the toxic effects of uranyl can 
be prevented by using chelating agent and complexation of the 
potentially multidentate ligands. 
Computational Studies 
Computational drug design is a new and advanced approach to 
predict the promising chemical species against a particular type of 
micro-organism. It also helps to understand how disease and 
infection are controlled at the molecular and physiological level and 
ultimately to target specific entities based on this knowledge. Many 
researchers have put forth their success stories in the use of 
Computer Aided Drug Design (CADD) for optimizing the lead and 
explaining the mechanism of action of specific entities for a number 
of targets, but very few references are available for 
thiosemicarbazide/thiosemicarbazone as lead compound in this 
direction.  
The mode of inhibitory action of 4-ethoxycarbonylmethyl-1-
(piperidin-4-ylcarbonyl)-thiosemicarbazideHydrochloride (IX) was 
examined by performing docking simulations with ATP-binding 
domain of hTopoIIα(PDB: 1ZXM) and DNA binding site of hTopoIIβ 
(PDB id: 3QX3) using the FlexX program, which has been shown to 
be reliable enough to carry out binding mode analysis of ligands in 
ATP binding pocket of hTopoIIα [55]. Compound (IX) was docked 
into the DNA and ATP binding sites, respectively, wherein in both 
the cases, crystallographic water molecules were treated rotatable 
and displaceable. Their contribution to binding was found negligible 
in all cases and its free energies of binding obtained from the Hyde 
scoring function [56-57], was 9 kJ/mol in the DNA active site, while 
−20 kJ/mol in the ATP binding site Results clearly indicated that M 
has greater affinity toward the ATP binding site than to the DNA 
binding pocket of hTopoIIα and is an even more effective inhibitor 
than AMPPNP. (IX)formed 11 hydrogen bonding interactions with 
water molecules, Gly164, Asn163, Arg162, Glu87, Gly166, Tyr165 
and hydrophobic interactions with Gly160, Gly161, Asn91. 
Followed by docking studies, (IX) has been subjected to a 
preliminary MTT assay in estrogen receptor-positive (MCF-7) and 
estrogen receptor-negative (MDA-MB-231) breast cancer cells and 
was found to decrease the number of viable cells in both the types. 
The inhibitory activities (IC50) of compound M on MDA-MB-231 and 
MCF-7 were 146±2 and 132±2 μM, respectively. Further, 
cytotoxicity of (IX) was more pronounced at shorter times in MDA-














The studies were corroborated by a cell proliferation assay in which 
the profiles of DNA synthesis were found to be similar in MCF-7 and 
MDA-MB-231. The concentration of (IX) required to inhibit [3H]-
thymidine incorporation into DNA by 50 % (IC50) in MDA-MB-231 
was found to be 123±2 μM, suggesting a lower cytotoxic potency 
compared to chlorambucil (IC50056±2 μM). The concentrations of 
(IX) and chlorambucil required for 50 % inhibition of [3H]-
thymidine incorporation into DNA in breast cancer MCF-7 cells 
(IC50) were 124±2 μM and 65±2 μM, respectively [58]. 
Mode of action of anticancer drugs 
Cancer is the uncontrolled growth of cells coupled with malignant 
behavior: invasion and metastasis (among other features) [59] and 
is caused by the interaction between genetic susceptibility and 
environmental factors [60-61]. The available anticancer drugs have 
distinctly different mechanisms of action which may vary at 
different drug concentrations and in their effects on different types 
of normal and neoplastic cells. There are very few demonstrable 
biochemical differences between cancerous cells and normal cells. 
For this reason the effectiveness of many anticancer drugs is limited 
by their toxicity to normal rapidly growing cells in the intestinal and 
bone marrow areas. It is important to know that how anticancer 
drugs act at the cellular level to inhibit the growth of, or to destroy, 
susceptible cells. Most chemotherapeutic drugs work by impairing 
mitosis (cell division), effectively targeting fast-dividing cells and are 
cytotoxic in nature. As chemotherapy affects cell division, tumors 
with high growth rates are more sensitive to chemotherapy, as a 
larger proportion of the targeted cells are undergoing cell division at 
any time. Malignancies with slower growth rates, such as indolent 
lymphomas, tend to respond to chemotherapy much more modestly 
[62]. The role of anticancer drugs is to slow and hopefully stop the 
growth and spreading of cancer. There are three possible ways 
which can be helpful in meeting the goals associated with the use of 
the most commonly-used anticancer agents. 
1. Damaging the DNA of the affected cancer cells. 
2. Inhibition of the synthesis of new DNA strands to stop the cell 
from replicating, which permits the tumor to grow. 
3. Stopping mitosis of the original cell into two new cells.  
In a broader sense, the mode of action and action sites for anticancer 
drugs in the body can be depicted in fig. 1 [63]. 
Damaging the DNA of the affected cell 
These agents chemically damage DNA and RNA and disrupt the 
replication of DNA by either totally stopping replication or 
manufacturing useless DNA or RNA w. r. t. the growth of malignant 
cells. Examples of drugs in this class include cisplatin (Platinol®) 
and 7) antibiotics-daunorubicin (Cerubidine®), doxorubicin 
(Adriamycin®) and etoposide (VePesid®). 
Inhibition of the synthesis of new DNA strands 
Folic acid, heterocyclic bases and nucleotides are the building blocks 
for DNA and are made naturally within the cells. Agents under this 
category block one or other step in the formation of nucleotides, not 
permitting the synthesis of DNA and RNA in turn stopping the 
process of replication. Examples of drugs in this class include 
methotrexate (Abitrexate®), fluorouracil (Adrucil®),hydroxyurea 
(Hydrea®) and mercaptopurine (Purinethol®). 
Singhal et al. 











Fig. 1 It shows mode of action of anticancer agents [63]  
 
Stopping mitosis of the original cell into two new cells 
Mitotic spindles help the cell to split. These drugs disrupt the 
formation of these spindles and therefore interrupt cell division. 
Examples of drugs in this class include: vinblastine (Velban®), 
vincristine (Oncovin®) and pacitaxel (Taxol®). 
Toxicity by Anticancer Drugs 
Toxicity is the side effect caused by the drugs administered for the 
treatment of a particular disease. Various chemotherapeutic agents 
alone or in combination are used for the treatment of variety of 
neoplastic diseases in conjunction with surgery, radiotherapy and 
immunotherapy. Clinically useful antineoplastic agents exhibit 
selective toxicity to malignant cells. The antineoplastic agents have 
lowest therapeutic indices of any drug and as such they cause 
frequent and predictable multi-system toxicity [64]. Approaches to 
the reduction of chemotherapy-induced toxicity include dose 
reduction, use of alternate drugs or their analogues, growth factors, 
and cytoprotective agents [64]. Common toxicities encountered are 
haematological, gastrointestinal, skin and hair follicle toxicity, 
nervous system toxicity, local toxicity, metabolic abnormalities, 
hepatic toxicity, urinary tract toxicity, cardiac toxicity, pulmonary 
toxicity, gonadal toxicity etc. [65]. Acute and chronic marrow 
damage [66], deprivation of formed elements, incidence of life 
threatening haemorrhage and infection [67] are the common side 
effects under haematological toxicity and can be managed by 
reducing the dose quantity or even hospitalization depending upon 
the stage of toxicity caused to the patient. Common drugs 
responsible for these side effects are oxaliplatin, cyclophosphamide, 
cytarabine, ifosamide and many others. Anaemia in cancer patients 
is also multifactorial including blood loss [68] and the symptoms are 
associated with mild to moderate anaemia, negatively affecting 
person’s normal functional ability and quality of life. Cisplatine, 
altretamine, topotecan, docetaxel, cytarabine and paclitaxel are 
anticancer drugs responsible for anemia. Anorexia, nausea and 
vomiting are frequently observed after chemotherapy. Commonly 
nausea begins 4 to 6 hrs after treatment and lasts for 1 to 2 days. In 
patients whose cancer has resulted in debility or immobility, or in 
those who require narcotic analgesics, constipation can be a 
particular problem. Many medications can cause constipation. 
Constipation may also develop in patients who have received 
neurotoxic chemotherapeutic agents. Decreased bowel motility due 
to intra-abdominal disease, hypercalcemia or dehydration can also 
contribute to constipation [69]. Chemotherapy, radiotherapy, cancer 
itself, medications, supplemental feedings, anxiety and infection 
with bacteria like Clostridium difficile are the main causes of 
diarrhea. Methotrexate, cytarabine, nitrosourea, paclitaxel, 
irinotecan and floxuridine are anticancer drugs causing diarrhoea. 
Chemotherapy induced hair loss is not necessarily a serious 
physiologic complication but psychologically it can be one of the 
most devastating side effects. It is due to toxic effect of drug on 
rapidly dividing hair bulb. It can cause severe emotional impacts in 
some patients. It is dose dependant. Other terminal hair follicles 
such as those of eyebrows, eyelashes, beard, auxiliary and pubic 
hairs are variably affected. The hair usually regrows normally after 
completion of therapy. The anticancer drugs causing hair follicle 
toxicity are Paclitaxel, Ifosamide, etoposide, methotrexate, 
doxorubicine, Daunorubicine, cyclophophamaide and 
vincristine[70]. The incidence of neurotoxicity associated with 
chemotherapy is increasing because of greater use of high dose 
chemotherapy. Vincristine is the most important antineoplastic 
agent that has a dose limiting neurotoxicity. Paresthesia of hands 
and feet, loss of deep tendon reflexes and weakness are the most 
common symptoms in almost all patients.  
Accidental extravasations (reaction due to leakage or infiltration of 
drug into the subcutaneous tissues) have been reported in 0.1 to 
0.6% of patients. Cancer patients are more prone to drug 
extravasations because of many reasons during treatment, one being 
multiple over puncture. Doxorubicin, daunorubicin, 
mechlorethamine, mitomycin, vinblastine, vincristine and 
iodorubicin are major drugs causing extravasations. Urinary tract 
toxicity varies from renal tubular damage by Cisplatin and 
methotrexate to haemorrhagic cystitis (10%) by cyclophosphamide 
[71]. An increased incidence of bladder carcinoma is associated with 
prolonged use of these drugs. Chemotherapeutic drugs can damage 
directly or indirectly, lung tissue both of endothelial and epithelial 
cells [72]. Clinical presentations of pulmonary toxicity are acute 
pneumonitis, pulmonary fibrosis, hypersensitivity pneumonitis, 
non-cardiogenic pulmonary edema. Hypersensitivity and metabolic 
disorders are the other side effects associated with anticancer drugs. 
CONCLUSION 
The anticancer effects of thiosemicarbazones were once solely 
attributed to the inhibition of ribonucleotide reductase, an enzyme 
involved in the rate-limiting step of DNA synthesis. However, the 
mechanism behind this inhibition was initially not described. The 
ability of thiosemicarbazones to chelate metal ions has now been 
recognized as a major factor in their antiproliferative effects. The 
more reasonable explanation for the higher activity by the metal-
thiosemicarbazone complexes when compared to free ligands passes 
through the prevalence of the diffusive mechanism over the active 
transport mechanism across the membranes. The chelation of the 
metal ion by the most polar regions of the ligands (the donor atoms) 
allows an easier uptake by the cell. In vivo analysis indicates that 
some thiosemicarbazones show potential as chemotherapeutic 
agents. However, future study is warranted. 
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